- Home
- NRIX vs HQH Comparison
NRIX vs HQH Comparison
Compare NRIX & HQH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- HQH
- Stock Information
- Founded
- NRIX 2009
- HQH 1986
- Country
- NRIX United States
- HQH United States
- Employees
- NRIX N/A
- HQH N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- HQH Finance Companies
- Sector
- NRIX Health Care
- HQH Finance
- Exchange
- NRIX Nasdaq
- HQH Nasdaq
- Market Cap
- NRIX 1.1B
- HQH 788.2M
- IPO Year
- NRIX 2020
- HQH N/A
- Fundamental
- Price
- NRIX $9.64
- HQH $15.27
- Analyst Decision
- NRIX Strong Buy
- HQH
- Analyst Count
- NRIX 17
- HQH 0
- Target Price
- NRIX $30.71
- HQH N/A
- AVG Volume (30 Days)
- NRIX 999.6K
- HQH 183.8K
- Earning Date
- NRIX 04-08-2025
- HQH 01-01-0001
- Dividend Yield
- NRIX N/A
- HQH 11.56%
- EPS Growth
- NRIX N/A
- HQH N/A
- EPS
- NRIX N/A
- HQH 1.09
- Revenue
- NRIX $56,417,000.00
- HQH N/A
- Revenue This Year
- NRIX $15.73
- HQH N/A
- Revenue Next Year
- NRIX N/A
- HQH N/A
- P/E Ratio
- NRIX N/A
- HQH $15.24
- Revenue Growth
- NRIX N/A
- HQH N/A
- 52 Week Low
- NRIX $8.18
- HQH $14.31
- 52 Week High
- NRIX $29.56
- HQH $17.94
- Technical
- Relative Strength Index (RSI)
- NRIX 36.33
- HQH 41.34
- Support Level
- NRIX $11.05
- HQH $16.02
- Resistance Level
- NRIX $11.56
- HQH $16.42
- Average True Range (ATR)
- NRIX 0.64
- HQH 0.33
- MACD
- NRIX -0.04
- HQH 0.00
- Stochastic Oscillator
- NRIX 18.45
- HQH 19.30
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About HQH abrdn Healthcare Investors Shares of Beneficial Interest
abrdn Healthcare Investors Formerly Tekla Healthcare Investors is the United States based non-diversified closed-end management investment company. Its objective is to seek long-term capital appreciation by investing in securities of healthcare companies. In addition, the fund seeks to provide regular distribution of realized capital gains. The fund invests in the securities of public and private companies.